RWJ 676070

Drug Profile

RWJ 676070

Alternative Names: JNJ-17158063; RWJ-676070

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class Benzazepines; Spiro compounds; Vasodilators
  • Mechanism of Action Vasopressin 1a receptor antagonists; Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Heart failure; Hyponatraemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hyponatraemia in USA (PO)
  • 16 Apr 2009 Phase-I clinical trials in Congestive heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top